ICON

ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It specializes in the strategic development, management and analysis of programs that support clinical development. The company was founded by John Climax and Ronan Lambe in June 1990 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ICON (ICLR) reports robust earnings, eyes strategic partnerships for growth

ICON's Q4 2022 earnings reflect strong financial performance and strategic advancements. While facing challenges in pricing and COVID-related headwinds, the company is well-positioned to capitalize on growth opportunities through margin maintenance, strategic partnerships, and M&A focus.

ICON (ICLR) reports stable Q1 earnings, eyes growth amid challenges

ICON's Q1 2023 earnings call highlighted solid financial performance, strategic partnerships, and investments in innovation. While facing challenges in pricing negotiations and biotech funding, the company remains resilient and focused on growth opportunities. Stabilizing backlog burn rates, leveraging innovative tools, and addressing labor market dynamics present avenues for future success.

ICON reports solid Q2 performance and eyes growth opportunities

ICON's Q2 performance reflects growth momentum and strong financial outlook for 2023. Challenges include growth uncertainty and revenue predictability amid customer fluctuations. Opportunities lie in strategic partnerships, margin improvement, and market expansion.

ICON (ICLR) posts robust Q3 results, eyes growth amid challenges

ICON (ICLR) reports strong Q3 earnings, emphasizing revenue growth, strategic partnerships, and operational improvements. The company faces challenges from macroeconomic factors and customer concentration but sees opportunities in RFP growth and R&D budget expansion. With a focus on innovation and adaptability, ICON aims to maintain its strong performance and capitalize on future opportunities.

ICON (ICLR) reports strong Q4 earnings, eyes strategic growth

ICON's strong performance in Q4 and 2023 driven by revenue growth and margin improvement
Challenges include customer concerns over R&D spend and wide revenue guidance range for 2024
Opportunities lie in new partnerships, automation for margin expansion, and capital deployment priorities
Overall, ICON remains competitive, with positive outlook for future growth and development

ICON (ICLR) reports strong Q1 earnings and strategic growth outlook

ICON (ICLR) delivered a strong performance in Q1 2024, with robust financial results, strategic initiatives, and updated guidance reflecting confidence in future prospects.
While facing challenges such as revenue fluctuations and analyst inquiries, the company's strengths in client engagement, operational efficiency, and market positioning provide a solid foundation for growth.
Opportunities in M&A, customer base diversification, and data strategy underscore potential avenues for expansion and innovation, positioning ICON well for continued success in the industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It specializes in the development, management and analysis of programs that support clinical development. It operates through the following geographical segments: Ireland, Rest of Europe, U.S. and Other. The company was founded by John Climax and Ronan Lambe in June 1990 and is headquartered in Dublin, Ireland.

DUBLIN--(BUSINESS WIRE)--ICON plc to Present at the Barclays Global Healthcare Conference and the KeyBanc Capital Markets' Life Sciences & MedTech Investor Forum

ICON plc to Present at the Barclays Global Healthcare Conference and the KeyBanc Capital Markets' Life Sciences & MedTech Investor Forum

Icon PLC (ICLR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Icon PLC (ICLR) Surges 4.6%: Is This an Indication of Further Gains?

ICON Public Limited Company (ICLR) CEO Steve Cutler on Q4 2020 Results - Earnings Call Transcript

PRA Health Sciences

ICON plc, (NASDAQ: ICLR) recently announced it entered into a definitive agreement to acquire PRA Health Sciences, Inc. (NASDAQ: PRAH) in a deal valued at $12 billion. These are the details.

ICON (ICLR) To Buy PRA Health Sciences (PRAH) In $12 Billion Deal

NEW YORK, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of PRA Health Sciences, Inc. (NASDAQ: PRAH) breached their fiduciary duties or violated the federal securities laws in connection with the company's acquisition by ICON plc (NASDAQ: ICLR).

PRA HEALTH SCIENCES ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of PRAH and Encourages Investors to Contact the Firm

DUBLIN--(BUSINESS WIRE)--ICON Reports Fourth Quarter and Full Year 2020 Results

ICON Reports Fourth Quarter and Full Year 2020 Results

DUBLIN--(BUSINESS WIRE)--ICON to acquire PRA Health Sciences, creating a world leader in Healthcare Intelligence and Clinical Research

ICON to Acquire PRA Health Sciences, Creating a World Leader in Healthcare Intelligence and Clinical Research

Icon PLC (ICLR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Icon PLC (ICLR) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced the release of two new digital solutions supporting clinical research sites and sponsors. The FIRECREST suite of digital clinical solutions are now integrated with the ICON Safety Reporting solution to enable electronic acknowledgement of safety letters by principal investigators, with full compliance t

ICON Launches FIRECREST Safety Letters and Site Question Management Supporting Regulatory Compliance and Increasing Site Support

Icon PLC (ICLR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Icon PLC (ICLR) Beat Estimates Again in Its Next Earnings Report?

DUBLIN, Ireland--(BUSINESS WIRE)--ICON plc to Present at the 39th Annual JP Morgan Healthcare Conference

ICON plc to Present at the 39th Annual JP Morgan Healthcare Conference

BioNTech SE

Pfizer

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ:ICLR), a global provider of outsourced drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries and government and public health organisations, today announced it provided clinical trial services to the Pfizer (NYSE:PFE) and BioNTech SE (Nasdaq: BNTX) investigational COVID-19 vaccine programme. Pfizer and BioNTech were the first to announce positive efficacy results from a Phase 3, la

ICON Supports Pfizer and BioNTech on the Investigational COVID-19 Vaccine Trial

DUBLIN--(BUSINESS WIRE)--ICON plc to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference and Evercore ISI HealthCONx Conference

ICON plc to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference and Evercore ISI HealthCONx Conference

ICON Public Limited Company (ICLR) CEO Steve Cutler on Q3 2020 Results - Earnings Call Transcript

Icon PLC (ICLR) delivered earnings and revenue surprises of 10.97% and 5.54%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Icon PLC (ICLR) Tops Q3 Earnings and Revenue Estimates

Shares of Icon (NASDAQ:ICLR) moved lower by 0.6% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 1.15% year over year to $1.72, which beat the estimate of $1.53.

Recap: Icon Q3 Earnings

DUBLIN, Ireland--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries and government and public health organisations, has been re-selected by the Biomedical Advanced Research and Development Authority (BARDA) to continue being part of its exclusive Medical Countermeasures Clinical Studies Network (CSN). BARDA, part of the Office of the Assistant Secretary f

BARDA reselects ICON as preferred partner to help strengthen US emergency preparedness and response

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries and government and public health organisations, today announced it has been awarded Best Clinical Research Organisation (CRO) at the Vaccine Industry Excellence (ViE) Awards. ICON was presented with the award at the World Vaccine Congress which took place virtually last week. The ViE awards were c

ICON Wins Best CRO at the Vaccine Industry Excellence Awards

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries and government and public health organisations, today announced that it is launching Accellacare a global clinical research network offering patients easier and faster access to innovative treatments and offering customers the option to deploy decentralised trials. The site network includes previo

ICON Launches Accellacare a Global Clinical Research Network Focused on Increasing Patient Recruitment With a Patient Centric Approach

DUBLIN--(BUSINESS WIRE)--ICON plc to Present at Wells Fargo 2020 Virtual Global Healthcare Conference and Baird 2020 Global Healthcare Conference

ICON plc to Present at Wells Fargo 2020 Virtual Global Healthcare Conference and Baird 2020 Global Healthcare Conference

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a leading global provider of drug development and commercialisation services to the pharmaceutical, biotechnology and medical device industries today announced that it has been recognised in the 2020 Forbes List of America’s Best Employers for Women for the second consecutive year. Forbes collaborated with market research firm Statista, surveying 75,000 Americans, including 45,000 women, working for businesses that employ more than 1,000 workers

Forbes names ICON in list of Best Employers in America for Women

ICON's (ICLR) CEO Steven Cutler on Q2 2020 Results - Earnings Call Transcript

Shares of Icon (NASDAQ:ICLR) were unchanged after the company reported Q2 results.

Icon: Q2 Earnings Insights

Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Icon PLC (ICLR) Q2 Earnings Expected to Decline

Strayer Education

Workday

Wayfair stock benefited from the novel coronavirus and is up big year to date. It’s time to consider other stocks.

News for ICON Stock (ICLR)